SYK and atherosclerosis: Our finding that Syk deletion suppressed atherosclerosis is consistent with a previous study demonstrating that the SYK-specific inhibitor fostamatinib, approved by the FDA for chronic idiopathic thrombocytopenic purpura,37 suppressed the development of atherosclerosis in mice.38